Clinical trials: sponsored by Genmab
Non-CNS Tumor
A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors
The main purpose is to assess the safety and clinical activity of GEN1042 in combination with radiotherapy or GEN1042 in combination with radiotherapy and pembrolizumab as a treatment option for participants with metastatic solid…
- Trial name
- NCT05491317
- Testing
- GEN1042, Pembrolizumab, Radiotherapy
- Where
- 2 sites in France
- Volunteers
- 13 people
- Sponsor
- Genmab
Malignant Solid Tumor
Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy
The goal of this trial is to learn about the antibody GEN1055 when it is used alone and when it is used together with another antibody cancer drug, pembrolizumab (with or without chemotherapy), for treatment of participants with…
- Trial name
- NCT06391775
- Testing
- GEN1055, Pembrolizumab, Standard Chemotherapy
- Where
- 4 sites in United States, Spain
- Volunteers
- 21 people
- Sponsor
- Genmab
Follicular Lymphoma (FL)
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
Follicular lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all…
- Trial name
- EPCORE™FL-2 (NCT06191744)
- Testing
- Epcoritamab, Prednisone, Rituximab
- Where
- 266 sites in United States, Australia and 30 more
- Volunteers
- 1,095 people
- Sponsor
- Genmab
Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC)
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
The goal of this trial is to learn about the antibody GEN1042 when it is used alone and when it is used together with another antibody cancer drug, pembrolizumab (with or without chemotherapy), for treatment of participants with…
- Conditions
- Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Melanoma
- Trial name
- NCT04083599
- Testing
- GEN1042, Pembrolizumab, Cisplatin
- Where
- 76 sites in United States, Denmark and 10 more
- Volunteers
- 350 people
- Sponsor
- Genmab
Breast Cancer, Breast Neoplasms, Endometrial Cancer, Endometrial Neoplasm
GEN1047 for Solid Tumors - First in Human (FIH) Trial
The purpose of this trial is to measure the following in participants with solid tumors who receive GEN1047: The side effects seen with GEN1047 What the body does with GEN1047 once it is administered What GEN1047 does to the body…
- Conditions
- Breast Cancer, Breast Neoplasms, Endometrial Cancer, Endometrial Neoplasm, Ovarian Cancer, Ovarian Neoplasms, Squamous Non Small Cell Lung Cancer (NSCLC-SCC)
- Trial name
- NCT05180474
- Testing
- GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive tumor cells.
- Where
- 36 sites in United States, Belgium and 7 more
- Volunteers
- 179 people
- Sponsor
- Genmab
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
This trial will study tisotumab vedotin to find out whether it is an effective treatment alone or with other anticancer drugs for certain solid tumors and what side effects (unwanted effects) may occur.
- Conditions
- Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
- Trial name
- innovaTV 207 (NCT03485209)
- Testing
- tisotumab vedotin, pembrolizumab, carboplatin
- Where
- 175 sites in United States, Canada and 5 more
- Volunteers
- 350 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Cervical Cancer
Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer
This is an open label, multi-center trial of tisotumab vedotin monotherapy and in combination with bevacizumab, pembrolizumab, or carboplatin in subjects with recurrent or stage IVB cervical cancer.
- Trial name
- NCT03786081
- Testing
- Tisotumab Vedotin, Bevacizumab, Pembrolizumab
- Where
- 71 sites in United States, Belgium and 8 more
- Volunteers
- 214 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma
Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients
This phase I trial tests the safety, side effects and best dose of epcoritamab alone and epcoritamab with polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R- mini-CHP) for the treatment of…
- Conditions
- Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma
- Trial name
- NCT07714421
- Testing
- Biospecimen Collection, Computed Tomography, Cyclophosphamide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Advanced Solid Tumor
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors
The purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics (PK), anti-tumor activity and immunogenic potential of GEN1286 in participants with advanced solid tumors.
- Trial name
- NCT06685068
- Testing
- GEN1286
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- Genmab
Large Cell Lymphoma, Diffuse, Relapsed Cancer
Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
Subjects with relapsed large cell lymphoma will receive 3 cycles of combination therapy consisting of GDP and epcoritamab. Each cycle will last 21 days.
- Conditions
- Large Cell Lymphoma, Diffuse, Relapsed Cancer, Refractory Cancer
- Trial name
- NCT05852717
- Testing
- AutoSCT OR CAR T-cell Therapy, GDP, Epcoritamab
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- Dipenkumar Modi
Follicular Lymphoma (FL)
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
Follicular Lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all…
- Trial name
- EPCORE FL-1 (NCT05409066)
- Testing
- Epcoritamab, Rituximab, Lenalidomide
- Where
- 273 sites in United States, Argentina and 28 more
- Volunteers
- 549 people
- Sponsor
- Genmab
Non-Hodgkin Lymphoma
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections).
- Trial name
- NCT05283720
- Testing
- Epcoritamab, Lenalidomide, Ibrutinib
- Where
- 76 sites in United States, China and 11 more
- Volunteers
- 264 people
- Sponsor
- Genmab
Metastatic Colorectal Cancer
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
This randomized, multi-site, three-part study will test a new treatment called BNT314, which is designed to help the body's own defense to fight cancer in combination with another new treatment (pumitamig, which is a cancer…
- Trial name
- NCT07079631
- Testing
- BNT314, Pumitamig, SoC chemotherapy treatment 1
- Where
- 14 sites in United States, Germany and 3 more
- Volunteers
- 482 people
- Sponsor
- BioNTech SE
Non-Hodgkin Lymphoma, Cytokine Release Syndrome
Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
The goal of this clinical trial is to is to determine the safety, feasibility and efficacy of siltuximab prophylaxis of cytokine release syndrome and neurotoxicity occurring after epcoritamab subcutaneous administration for…
- Trial name
- NCT06447376
- Testing
- Siltuximab, Epcoritamab, Gemcitabine and oxaliplatin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Taylor Brooks
Endometrial Cancer, Ovarian Cancer
PRO1107 in Patients With Advanced Solid Tumors
This is a global, open-label, multicenter Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of GEN1107 (PRO1107) in participants with advanced solid tumors.
- Conditions
- Endometrial Cancer, Ovarian Cancer, Triple Negative Breast Cancer, GastroEsophageal Cancer
- Trial name
- NCT06171789
- Testing
- GEN1107
- Where
- 7 sites in United States, China
- Volunteers
- 33 people
- Sponsor
- Genmab
Lymphoma, Non-Hodgkin, Relapsed Diffuse Large B Cell Lymphoma
Epcoritamab-CAR T Cells for Large B-cell Lymphomas
This study investigates the feasibility and efficacy of epcoritamab treatment before CAR T cells. This study also investigates if, when patients have residual lymphoma after CAR T cells, epcoritamab can help to effectively treat…
- Conditions
- Lymphoma, Non-Hodgkin, Relapsed Diffuse Large B Cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma
- Trial name
- NCT06458439
- Testing
- Epcoritamab
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Diffuse Large B-cell Lymphoma
A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
The purpose of this trial is to find out if epcoritamab, also known as EPKINLY™ and GEN3013, is safe and works well as treatment for participants with DLBCL that are not responding to treatment, have grown in size, or have come…
- Trial name
- EPCORE DLBCL-1 (NCT04628494)
- Testing
- Epcoritamab, Investigator's Choice Chemotherapy
- Where
- 186 sites in United States, Australia and 22 more
- Volunteers
- 483 people
- Sponsor
- Genmab
Follicular Lymphoma, Low Grade Non-Hodgkin's Lymphoma, Adult
Epcoritamab and Rituximab for First-line Follicular Lymphoma
The purpose of this study is to determine how effective and safe the combination of rituximab and epcoritamab is in treating patients with Follicular Lymphoma (FL) and who have not received other treatments for their lymphoma.
- Trial name
- NCT05783609
- Testing
- Epcoritamab, Rituximab
- Where
- 6 sites in United States
- Volunteers
- 100 people
- Sponsor
- Reid Merryman, MD
Relapsed or Refractory Multiple Myeloma (RRMM), Diffuse Large B Cell Lymphoma (DLBCL)
GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies
The drug that will be investigated in the study is an antibody, GEN3014. Since this is the first study of GEN3014 in humans, the main purpose is to evaluate safety.
- Conditions
- Relapsed or Refractory Multiple Myeloma (RRMM), Diffuse Large B Cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML)
- Trial name
- NCT04824794
- Testing
- GEN3014, Daratumumab
- Where
- 52 sites in United States, Australia and 18 more
- Volunteers
- 130 people
- Sponsor
- Genmab
Diffuse Large B-Cell Lymphoma
A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China
The purpose of this Chinese sub-study trial is to find out if epcoritamab, also known as EPKINLY™ and GEN3013, is safe and works well as treatment for participants with DLBCL that are not responding to treatment, have grown in…
- Trial name
- NCT07226752
- Testing
- Epcoritamab, Investigator's Choice Chemotherapy
- Where
- 23 sites in China
- Volunteers
- 72 people
- Sponsor
- Genmab